Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
100 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vasculitis - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Vasculitis - Pipeline Review, H1 2016', provides an overview of the Vasculitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vasculitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Vasculitis - The report reviews pipeline therapeutics for Vasculitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Vasculitis therapeutics and enlists all their major and minor projects - The report assesses Vasculitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Vasculitis Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Vasculitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Vasculitis Overview 8 Therapeutics Development 9 Pipeline Products for Vasculitis - Overview 9 Pipeline Products for Vasculitis - Comparative Analysis 10 Vasculitis - Therapeutics under Development by Companies 11 Vasculitis - Therapeutics under Investigation by Universities/Institutes 12 Vasculitis - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Vasculitis - Products under Development by Companies 17 Vasculitis - Products under Investigation by Universities/Institutes 18 Vasculitis - Companies Involved in Therapeutics Development 19 AnGes MG, Inc. 19 ChemoCentryx, Inc. 20 Coherus BioSciences, Inc. 21 Epirus Biopharmaceuticals, Inc. 22 F. Hoffmann-La Roche Ltd. 23 GlaxoSmithKline Plc 24 Hemostemix Ltd 25 Johnson & Johnson 26 K-Stemcell Co., Ltd. 27 Panacea Biotec Limited 28 Pfizer Inc. 29 Sandoz International GmbH 30 Stempeutics Research Private Limited 31 Teijin Pharma Limited 32 Vasculitis - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 42 ACP-01 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 belimumab - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 beperminogene perplasmid - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CCX-168 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Drug to Target Mac-1 for Vasculitis and Glomerulonephritis - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 immune globulin (human) - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 PF-1355 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 rituximab biosimilar - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 rituximab biosimilar - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 rituximab biosimilar - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 rituximab biosimilar - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 sirukumab - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Stem Cell Therapy for Thromboangiitis - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Stempeucel - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 tocilizumab - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Vasculitis - Recent Pipeline Updates 74 Vasculitis - Dormant Projects 92 Vasculitis - Product Development Milestones 93 Featured News & Press Releases 93 Nov 25, 2015: GSK announces start of phase III study of sirukumab in Giant Cell Arteritis 93 Jun 01, 2015: Stempeutics Receives Orphan Drug Designation (ODD) in the European Union for its Novel Stem Cell Drug "Stempeucel" for the Treatment of Thromboangiitis Obliterans 93 Mar 23, 2015: Stempeutics Receives Advanced Therapy Medicinal Product (ATMP) Classification From European Medicines Agency (EMA) for its Novel Stem Cell Drug 'Stempeucel' 94 Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 95 Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 95 Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis 95 Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal 96 May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress 96 Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis 97 Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology 98 Appendix 99 Methodology 99 Coverage 99 Secondary Research 99 Primary Research 99 Expert Panel Validation 99 Contact Us 99 Disclaimer 100
List of Tables
Number of Products under Development for Vasculitis, H1 2016 9 Number of Products under Development for Vasculitis - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Comparative Analysis by Unknown Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Vasculitis - Pipeline by AnGes MG, Inc., H1 2016 19 Vasculitis - Pipeline by ChemoCentryx, Inc., H1 2016 20 Vasculitis - Pipeline by Coherus BioSciences, Inc., H1 2016 21 Vasculitis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 22 Vasculitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 23 Vasculitis - Pipeline by GlaxoSmithKline Plc, H1 2016 24 Vasculitis - Pipeline by Hemostemix Ltd, H1 2016 25 Vasculitis - Pipeline by Johnson & Johnson, H1 2016 26 Vasculitis - Pipeline by K-Stemcell Co., Ltd., H1 2016 27 Vasculitis - Pipeline by Panacea Biotec Limited, H1 2016 28 Vasculitis - Pipeline by Pfizer Inc., H1 2016 29 Vasculitis - Pipeline by Sandoz International GmbH, H1 2016 30 Vasculitis - Pipeline by Stempeutics Research Private Limited, H1 2016 31 Vasculitis - Pipeline by Teijin Pharma Limited, H1 2016 32 Assessment by Monotherapy Products, H1 2016 33 Number of Products by Stage and Target, H1 2016 35 Number of Products by Stage and Mechanism of Action, H1 2016 37 Number of Products by Stage and Route of Administration, H1 2016 39 Number of Products by Stage and Molecule Type, H1 2016 41 Vasculitis Therapeutics - Recent Pipeline Updates, H1 2016 74 Vasculitis - Dormant Projects, H1 2016 92
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.